ADC · 폐암 (NSCLC)

14개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved14 programs
ADCCurated CoreFDADaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk)

HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
ADCStandard DatabaseFDAstaleDaiichi SankyoApproved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Approved#FDA-approved#antibody-drug-conjugate+3
Trials 24Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCStandard DatabasestaleDaiichi Sankyo Co., Ltd.Phase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 149Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyo Co., Ltd.deruxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 148Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCGovitecan in gynecologic ma…Phase 3

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan)

Non-small Cell Lung Cancer; Solid Tumors · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 57Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 45Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#antibody-drug-conjugate#Carcinoma+4
Trials 41Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Carcinoma, Non-Small-Cell Lung · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 7Status Recruiting
ADCStandard DatabasestaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

sigvotatug vedotin (sigvotatug vedotin)

Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small Cell Lung

#CarcinomaNon-SmallCellLung#ADC#Phase1#antibody-drug-conjugate#Carcinoma+3
Trials 5Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 4Status Recruiting
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting